Exane Derivatives’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Exane Derivatives’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$49	–	750
2018 Q3	$49	Hold	1	–	–	﹤0.01%	644
2018 Q2	$43	Hold	1	–	–	﹤0.01%	643
2018 Q1	$41	Sell	1 -3,626	-100%	-$158K	﹤0.01%	577
2017 Q4	$158K	Buy	3,627 +793	+28%	+$33.7K	0.03%	255
2017 Q3	$121K	Sell	2,834 -718	-20%	-$30.4K	0.02%	238
2017 Q2	$153K	Buy	+3,552	New	+$150K	0.03%	224
2017 Q1	–	Sell	-3,649	Closed	-$143K	–	688
2016 Q4	$143K	Buy	3,649 +1,902	+109%	+$77.4K	0.03%	219
2016 Q3	$77.2K	Buy	+1,747	New	+$79.3K	0.01%	258

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Exane Derivatives's XPH Position: Q4 2018 in Review

Exane Derivatives sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2018, closing a stake of 1 share — an estimated $49 sold.

Exane Derivatives first reported a position in XPH in Q3 2016 and held it in 8 quarters. The position peaked at $158K in Q4 2017. 74 funds tracked by Wall St. Rank hold XPH as of Q4 2018.

Exane Derivatives reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 1 State Street SPDR S&P Pharmaceuticals ETF share in Q4 2018, an estimated $49.
Exane Derivatives first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2016 and held it in 8 quarters.
Exane Derivatives's State Street SPDR S&P Pharmaceuticals ETF position peaked at $158K in Q4 2017.
74 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.